ACM
NVO

Arlington Capital Management’s Novo Nordisk NVO Stock Holding History

Arlington Capital Management’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$260K Buy
+5,422
New +$233K 0.16% 84
2026
Q1 		– Sell
-5,422
Closed -$276K – 126
2025
Q4 		$276K Buy
+5,422
New +$277K 0.17% 75
2024
Q2 		– Sell
-9,529
Closed -$1.22M – 98
2024
Q1 		$1.22M Buy
9,529
+9
+0.1% +$1.07K 1.02% 32
2023
Q4 		$985K Buy
+9,520
New +$941K 0.9% 34

Other funds holding NVO

Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
EHC
Everett Harris & Co Los Angeles, California $8.14B AUM 14.79% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return
SRIM
Saratoga Research & Investment Management Saratoga, California $1.83B AUM 18.41% 1-Year Est. Return
MG
Markel Group Glen Allen, Virginia $13.1B AUM 15.62% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
OAM
Oppenheimer Asset Management New York $9.63B AUM 30.32% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

Arlington Capital Management's NVO Position: Q2 2026 in Review

Arlington Capital Management opened a new position in Novo Nordisk (NVO) in Q2 2026: 5,422 shares worth $260K. The stake represents 0.16% of the portfolio and ranks #84 among its holdings. This is a return to the name: Arlington Capital Management previously reported a position in NVO as recently as Q4 2025.

Arlington Capital Management first reported a position in NVO in Q4 2023 and has held it in 4 quarters since. The position peaked at $1.22M in Q1 2024. 756 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Arlington Capital Management held 5,422 shares of Novo Nordisk worth $260K as of Q2 2026.
  • Novo Nordisk was a new Arlington Capital Management position in Q2 2026.
  • Novo Nordisk made up 0.16% of Arlington Capital Management's portfolio in Q2 2026, its #84 holding.
  • Arlington Capital Management first reported a position in Novo Nordisk in Q4 2023 and has held it in 4 quarters since.
  • Arlington Capital Management's Novo Nordisk position peaked at $1.22M in Q1 2024.
  • 756 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Arlington Capital Management's 13F filing for Q2 2026, filed 24 Jul 2026.